FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine and concerns a linker-active agent for preparing an antibody-drug conjugate containing a compound of formula I or its pharmaceutically acceptable salt. Group of inventions also relates to a targeting moiety-drug conjugate for treating HER2-positive cancer in a subject; method of treating HER2-positive cancer in a subject involves administering a targeting moiety-drug conjugate to a subject in need of such treatment.
EFFECT: group of inventions provides reduced rate of decomposition of the anticancer conjugate compared to known conjugates.
13 cl, 3 ex, 7 dwg, 4 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| LINKER FOR ANTIBODY-DRUG CONJUGATES AND THEIR USE | 2019 |
|
RU2792201C2 |
| PEPTIDOMIMETIC COMPOUNDS AND THEIR CONJUGATES OF ANTIBODIES WITH DRUGS | 2014 |
|
RU2689388C1 |
| MONOMETHYLVALINE COMPOUNDS CAPABLE OF FORMING CONJUGATES WITH LIGANDS | 2004 |
|
RU2448117C2 |
| BIFUNCTIONAL CYTOTOXIC AGENTS | 2015 |
|
RU2669807C2 |
| ANTI-MESOTHELIN ANTIBODY AND CONJUGATE THEREOF WITH MEDICINAL PRODUCTS | 2019 |
|
RU2747995C1 |
| STABILITY-MODULATING LINKERS FOR USE WITH ANTIBODY DRUG CONJUGATES | 2015 |
|
RU2680238C2 |
| CHEMOSELECTIVE THIOL-CONJUGATION WITH ALKENE- OR ALKYNE-PHOSPHONOTHIOLATES AND -PHOSPHONATES | 2019 |
|
RU2825582C2 |
| CYTOTOXIC PEPTIDES AND ANTIBODY-DRUG CONJUGATES THEREOF | 2012 |
|
RU2586885C2 |
| NOVEL ANTIBODY CONJUGATES AND USES THEREOF | 2014 |
|
RU2684468C2 |
| OLIGOPEPTIDE LINKER INTERMEDIATE AND METHOD FOR PRODUCTION THEREOF | 2019 |
|
RU2775973C1 |
